- Home
- CWBC vs YMAB Comparison
CWBC vs YMAB Comparison
Compare CWBC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWBC
- YMAB
- Stock Information
- Founded
- CWBC 1989
- YMAB 2015
- Country
- CWBC United States
- YMAB United States
- Employees
- CWBC N/A
- YMAB N/A
- Industry
- CWBC Major Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CWBC Finance
- YMAB Health Care
- Exchange
- CWBC Nasdaq
- YMAB Nasdaq
- Market Cap
- CWBC 398.6M
- YMAB 386.7M
- IPO Year
- CWBC 1996
- YMAB 2018
- Fundamental
- Price
- CWBC $21.36
- YMAB $8.53
- Analyst Decision
- CWBC Buy
- YMAB Buy
- Analyst Count
- CWBC 3
- YMAB 10
- Target Price
- CWBC $21.67
- YMAB $13.91
- AVG Volume (30 Days)
- CWBC 39.7K
- YMAB 2.0M
- Earning Date
- CWBC 07-17-2025
- YMAB 08-08-2025
- Dividend Yield
- CWBC 2.24%
- YMAB N/A
- EPS Growth
- CWBC 95.72
- YMAB N/A
- EPS
- CWBC 1.39
- YMAB N/A
- Revenue
- CWBC $132,829,000.00
- YMAB $85,385,000.00
- Revenue This Year
- CWBC $30.64
- YMAB N/A
- Revenue Next Year
- CWBC $6.58
- YMAB $13.97
- P/E Ratio
- CWBC $15.34
- YMAB N/A
- Revenue Growth
- CWBC 55.84
- YMAB N/A
- 52 Week Low
- CWBC $15.57
- YMAB $3.55
- 52 Week High
- CWBC $22.89
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- CWBC 69.49
- YMAB 81.62
- Support Level
- CWBC $19.97
- YMAB $8.50
- Resistance Level
- CWBC $20.36
- YMAB $8.54
- Average True Range (ATR)
- CWBC 0.48
- YMAB 0.02
- MACD
- CWBC 0.16
- YMAB 0.00
- Stochastic Oscillator
- CWBC 91.64
- YMAB 80.00
About CWBC Community West Bancshares
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the Company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.